SCYX · SCYNEXIS Inc. Common Stock
View on chartInsiders & Stakes
| Angulo Gonzalez David Chief Medical Officer | ▲ Buy | Open Market | 1,357,126 Shares held | 4/1/2026 | View profile |
| Sukenick Scott General Counsel | ▲ Buy | Grant | 574,539 Shares held | 1/29/2026 | View profile |
| Macleod ivor Chief Financial Officer | ▲ Buy | Grant | 398,529 Shares held | 1/29/2026 | View profile |
| Taglietti Marco Chief Executive Officer | ▲ Buy | Open Market | 272,068 Shares held | 4/26/2022 | View profile |
| GILMAN STEVEN C Director | ▲ Buy | Grant | 70,000 Shares held | 6/26/2025 | View profile |
| Coyne Christine Chief Commercial Officer | ▲ Buy | Grant | 58,200 Shares held | 2/4/2022 | View profile |
| Macdonald Guy Director | ▲ Buy | Grant | 12,625 Shares held | 6/26/2026 | View profile |
| Tinmouth Brian Philippe Director | ▲ Buy | Grant | 12,125 Shares held | 6/26/2026 | View profile |
| ANIDO ARMANDO Director | ▲ Buy | Grant | 11,750 Shares held | 6/26/2026 | View profile |
| HANHAM ANN Director | ▲ Buy | Grant | 11,577 Shares held | 6/26/2026 | View profile |
| David C. Hastings Director | ▲ Buy | Grant | 11,522 Shares held | 6/26/2026 | View profile |
| Burke Steven Keith SVP, Chief Medical Officer | ▲ Buy | Grant | 5,750 Shares held | 9/18/2026 | View profile |
Transaction History
| Burke Steven Keith | ▲ Buy | Grant | 5,750 | $0 | 9/18/2026 |
| David C. Hastings | ▲ Buy | Grant | 2,875 | $0 | 6/26/2026 |
| Tinmouth Brian Philippe | ▲ Buy | Grant | 2,875 | $0 | 6/26/2026 |
| Macdonald Guy | ▲ Buy | Grant | 2,875 | $0 | 6/26/2026 |
| ANIDO ARMANDO | ▲ Buy | Grant | 2,875 | $0 | 6/26/2026 |
| HANHAM ANN | ▲ Buy | Grant | 2,875 | $0 | 6/26/2026 |
| Angulo Gonzalez David | ▲ Buy | Open Market | 108,695 | — | 4/1/2026 |
| Macleod ivor | ▲ Buy | Grant | 129,833 | $0 | 1/29/2026 |
| Sukenick Scott | ▲ Buy | Grant | 129,833 | $0 | 1/29/2026 |
| Angulo Gonzalez David | ▲ Buy | Grant | 391,333 | $0 | 1/29/2026 |
| Angulo Gonzalez David | ▲ Buy | Grant | 32,500 | $25K | 10/17/2025 |
| Tinmouth Brian Philippe | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 |
| Macdonald Guy | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 |
| David C. Hastings | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 |
| HANHAM ANN | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 |
| GILMAN STEVEN C | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 |
| ANIDO ARMANDO | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 |
| Angulo Gonzalez David | ▲ Buy | Grant | 23,000 | $19K | 4/9/2025 |
| Angulo Gonzalez David | ▲ Buy | Grant | 13,800 | $14K | 3/20/2025 |
| Angulo Gonzalez David | ▲ Buy | Grant | 5,000 | $5K | 3/19/2025 |
| Sukenick Scott | ▲ Buy | Grant | 92,511 | $0 | 1/23/2025 |
| Macleod ivor | ▲ Buy | Grant | 92,511 | $0 | 1/23/2025 |
| Angulo Gonzalez David | ▲ Buy | Grant | 262,927 | $0 | 1/23/2025 |
| Angulo Gonzalez David | ▲ Buy | Open Market | 20,000 | $27K | 9/12/2024 |
| Macdonald Guy | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 |
| David C. Hastings | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 |
| GILMAN STEVEN C | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 |
| Tinmouth Brian Philippe | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 |
| ANIDO ARMANDO | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 |
| HANHAM ANN | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 |
| Sukenick Scott | ▼ Sell | Tax Withholding | 15,179 | $25K | 2/16/2024 |
| Angulo Gonzalez David | ▲ Buy | Grant | 290,590 | $0 | 1/26/2024 |
| Macleod ivor | ▲ Buy | Grant | 143,675 | $0 | 1/26/2024 |
| Sukenick Scott | ▲ Buy | Grant | 143,675 | $0 | 1/26/2024 |
| Tinmouth Brian Philippe | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 |
| ANIDO ARMANDO | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 |
| GILMAN STEVEN C | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 |
| HANHAM ANN | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 |
| David C. Hastings | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 |
| Macdonald Guy | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 |
| Sukenick Scott | ▲ Buy | Grant | 50,000 | $0 | 5/15/2023 |
| Sukenick Scott | ▲ Buy | Grant | 100,000 | $0 | 1/27/2023 |
| Angulo Gonzalez David | ▲ Buy | Grant | 110,000 | $0 | 1/1/2023 |
| Macleod ivor | ▲ Buy | Grant | 15,000 | $0 | 10/24/2022 |
| Tinmouth Brian Philippe | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 |
| Macdonald Guy | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 |
| David C. Hastings | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 |
| HANHAM ANN | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 |
| GILMAN STEVEN C | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 |
| ANIDO ARMANDO | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 |
| Taglietti Marco | ▲ Buy | Open Market | 75,000 | $225K | 4/26/2022 |
| Sukenick Scott | ▲ Buy | Open Market | 3,500 | $11K | 4/26/2022 |
| Taglietti Marco | ▲ Buy | Grant | 87,200 | $0 | 2/4/2022 |
| Sukenick Scott | ▲ Buy | Grant | 40,700 | $0 | 2/4/2022 |
| Coyne Christine | ▲ Buy | Grant | 43,200 | $0 | 2/4/2022 |
| Angulo Gonzalez David | ▲ Buy | Grant | 51,100 | $0 | 2/4/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SCYNEXIS Wins $214M BARDA Contract for SCY-247
SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.
SCYNEXIS Wins $214M BARDA Contract for SCY-247. SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.